← Back to Search

Virus Therapy

CIML-NK Cells for Acute Myeloid Leukemia

Phase 1 & 2
Recruiting
Led By Michele Wang
Research Sponsored by Children's Hospital Medical Center, Cincinnati
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Refractory disease: Patients must have ≥ 5% blasts in the bone marrow after 2 courses of intensive induction treatment
With relapsed or refractory AML in their bone marrow
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights

Study Summary

This trial tests if donor-derived memory-like NK cells can be safely infused to fight relapsed/refractory AML, to see if they are effective in treating the disease.

Who is the study for?
Adults diagnosed with relapsed or refractory acute myeloid leukemia (AML) who have a compatible family donor can join this trial. They must have at least 5% AML cells in their bone marrow and be able to perform daily activities at least half of the time. People with certain heart, lung, liver issues, uncontrolled infections, or on high-dose steroids cannot participate.Check my eligibility
What is being tested?
The study is testing if natural killer cells treated with cytokines from a relative's donated cells are safe and effective for treating AML that has come back or hasn't responded to other treatments.See study design
What are the potential side effects?
Potential side effects may include reactions related to immune system activation such as fever and fatigue, as well as possible infusion-related reactions. The full range of side effects will be monitored throughout the trial.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My leukemia did not respond well to initial treatments.
Select...
My AML has returned or didn't respond to treatment.
Select...
My leukemia has returned within 6 months after initial remission.
Select...
I can do most activities or chores without help, regardless of my age.
Select...
I have been diagnosed with acute myeloid leukemia.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Feasibility of infusion
Secondary outcome measures
Clinical Response to CIML-NK Infusion
Persistence of CIML-NK cells in the recipients' peripheral blood
Proceed to Hematopoietic Stem Cell Transplant (HSCT)

Trial Design

1Treatment groups
Experimental Treatment
Group I: Cytokine-Induced Memory-Like Natural Killer (CIML-NK) CellsExperimental Treatment1 Intervention
The investigational cell product is a cytokine-induced memory-like natural killer cell preparation, derived from the recipient's haploidentical donor's apheresis product.

Find a Location

Who is running the clinical trial?

Children's Hospital Medical Center, CincinnatiLead Sponsor
814 Previous Clinical Trials
6,531,561 Total Patients Enrolled
Michele WangPrincipal InvestigatorChildren's Hospital Medical Center, Cincinnati

Media Library

Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) (Virus Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT05580601 — Phase 1 & 2
Acute Myeloid Leukemia Research Study Groups: Cytokine-Induced Memory-Like Natural Killer (CIML-NK) Cells
Acute Myeloid Leukemia Clinical Trial 2023: Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) Highlights & Side Effects. Trial Name: NCT05580601 — Phase 1 & 2
Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) (Virus Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05580601 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many volunteers have signed up for this research endeavor?

"Yes, according to the data on clinicaltrials.gov this research is actively seeking volunteers. First posted on December 1st 2022 and most recently updated on November 30th 20202, 20 people are needed from a single location for enrolment in this study."

Answered by AI

Is enrollment for this research experiment still open?

"Affirmative. Information posted on clinicaltrials.gov suggests that this medical trial is currently recruiting participants; it was originally published in December 1st 2022, with the most recent update occurring November 30th of the same year. In total, 20 individuals need to be sourced from a single site."

Answered by AI
~10 spots leftby Feb 2025